Skip to content

Study on the establishment and application of the prediction and evaluation system for the drug efficacy and safety of individualized tumor therapy

Study on the establishment and application of the prediction and evaluation system for the drug efficacy and safety of individualized tumor therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RNC-16010210
Enrollment
Unknown
Registered
2016-12-21
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cancer, pancreatic cancer, lung cancer, gastric cancer and esophageal cancer

Interventions

Sponsors

The 81st Hospital of People’s Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteriafor liver cancer, pancreatic cancer, lung cancer, gastric cancer and esophageal cancer (common part): 1) Aged 18-75 years old; male or female patients; 2) Histopathological examination confirmed the diagnosis of cancer, and needs systematic anticancer therapy; 3) Can obtain fresh tumor tissues or pleural effusion or ascites samples by surgical resection or biopsy; 4) With tumor foci meeting the RECIST 1.1 standard; can evaluate the efficacy by CT/MRI; 5) ECOG PS 0-1; expected survival = 3 months; 6) Voluntary to participate and sign informed consent document; compliance is good, can actively treat and cooperate with follow-ups. Supplementary part: liver cancer:Patients with advanced hepatocellular carcinoma, to investigate the effect of As2O3, oxaliplatin and sorafenib. Pancreatic cancer: Patients with advanced pancreatic cancer, to investigate the effect of gemcitabine, oxaliplatin and Nab-paclitaxel; Not receiving radiotherapy and chemotherapy before operation; Clinical examination did not find other tumor disease; Karnofsky score=60; Bone marrow hematopoietic function is normal. lung cancer: Adjuvant therapy for stage II~IIIA non-small cell lung cancer (including adenocarcinoma, squamous cell carcinoma); Systemic treatment of locally advanced and / or metastatic non small cell lung cancer; Clinical examination did not find other tumor disease; expected survival =12weeks. Gastric cancer: Gastric cancer was confirmed by histopathology; Can obtain fresh tumor tissue specimens (surgery, endoscopy, puncture) or ascites samples. Esophageal cancer: Esophageal squamous cell carcinoma was confirmed by histopathology; Can obtain fresh tumor tissue specimens (surgery, endoscopy, puncture) or ascites samples.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

MeasureTime frame
Establish PDX model database;

Countries

China

Contacts

Public ContactShukui Qin

The 81st Hospital of People's Liberation Army

qinsk@csco.org.cn+86 025-80864541

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026